Publications.

The team of scientists at Herophilus develops groundbreaking advancements in biotechnology and machine learning. We aim to publish and share our findings with the global research community to collectively advance the fields of neurobiology, disease research and drug discovery.



Data science, human intelligence, and therapeutics discovery: An interview with Sean Escola, Saul Kato, and Pavan Ramkumar

8 April 2022 Cell Patterns

Herophilus leaders explain the importance of data science in their research, exploring a score that identifies hierarchical confounder effects in raw data and machine learning-derived data embeddings.

Getting real about curing polygenic brain disease.

1 March 2022 Herophilus

Lone single-target approaches, are doomed to fail in the quest to cure polygenic neurological diseases such as Alzheimer’s, schizophrenia, Parkinson’s, and autisms — ironically, common neurological diseases of high prevalence. A new approach is needed.

RTG: New methods for machine-learning confounder analysis.

22 February 2022 Cell Patterns

Explore how Herophilus approaches hierarchical confounder discovery in the experiment–machine learning cycle in recent paper in Cell Patterns.

Demuxalot: scaled up genetic demultiplexing for single-cell sequencing.

28 May 2021 BioRxiv

Herophilus is working on new methods in transcriptomic analysis. Read about our bioRxiv preprint and open source code release of Demuxalot.

Scaling brain organoids for disease phenotyping.

20 August 2020 bioRxiv

Learn how Herophilus optimizes the scaling of patient-derived brain organoids to uncover deep phenotypes of disease in our bioRxiv preprint.

Herohilus Uses AWS-Enabled Platform to Support Neurotherapeutics Modeling and Discovery.

16 April 2020 Amazon Web Services

Herophilus CTO Doug Flanzer discusses AWS technology and its role in our neurotherapeutics discovery pipeline at AWS HCLS 2020.

Herophilus introduces its mission at Brain Mind 2019.

16 December 2019 Brain Mind

Herophilus Co-Founder Sean Escola speaks about our mission at Brain Mind 2019.